Cancer Vaccines

  • Lindy G. Durrant
  • T. J. Declan Buckley
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 4)


In the past there was considerable evidence that cellular rather than antibody responses were more effective for tumor rejection (1). However, the task of identifying the tumor antigens recognized by T-cells was daunting technically. More recently there has been a growing optimism that the potential of tumor immunotherapy may at last be realized. This enthusiasm has been fed by a better understanding of the presentation and processing of peptides necessary for the induction of immune responses and the identification of new tumor targets. These developments will be discussed in this chapter. Because cancer vaccines are still in their infancy and largely experimental, detailed protocols for their production will not be presented.


Major Histocompatibility Complex Major Histocompatibility Complex Class Tumor Antigen Major Histocompatibility Complex Molecule Major Histocompatibility Complex Binding 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Robins, R. A. (1986) T-cell responses at the host: tumour mterface. Bzochim Blophys Acta 856, 289–305.Google Scholar
  2. 2.
    Rletbmuller, G., Scbneidergadicke, E., Schllmok, G., Scbmiegel, W, Raab, R., Hofken, K., Gruber, R., Plchlmaier, H., Hirche, H., Pichlmayr, R., Bugguch, P., Witte, J., Elgler, F W., Fracklerschwalbe, I., Funke, I, Schmidt, C G., Scbrelber, H., Schweiberre, L., and Elbleibesfeldt, B. (1994) Randomized trial for monoclonal antibody for adjuvant therapy of resected dukes-C colorectal carcinoma. Lancet 343,8907, 1177–1183CrossRefGoogle Scholar
  3. 3.
    Van den Eynde, B., Lethe, B., Van Pel, A., De Plaen, E, and Boon, T. (1993) The gene for coding for a major rejection antigen of tumor P815 is identical to the gene of syngenelc DBAl2 mice. J Exp. Med. 173, 1373–1378.CrossRefGoogle Scholar
  4. 4.
    Gaugler, B., Vandeneynde, B., Vanderbruggen, P., Romero, P., Gaforio, J., Deplaen, E., Lethe, B., Brasseu, F., and Boon, T. (1994) Human gene MAGE3 codes for an antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. J. Exp Med. 179, 921–930PubMedCrossRefGoogle Scholar
  5. 5.
    Brichard, V., Vanpel, A., Wolfel, T., Wolfel, C., Deplaen, E., Lethe, B., Coulie, P., and Boon, T. (1993) The tyrosmase gene codes for an antigen recognized by auotologous cytolytlc T-lymphocytes on HlA-A2-melanomas. J. Exp. Med. 2, 489–495.CrossRefGoogle Scholar
  6. 6.
    Bakker, A. B., Scbreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. (1994) Melanocyte lineage-specific antigen gp l00 is recogmsed by melanoma-denved tumour-infiltrating lymphocytes. J. Exp. Med. 179, 1005–1009.PubMedCrossRefGoogle Scholar
  7. 7.
    Kawakami, Y., Ehyahu, S., Delgado, C. H., Robbms, P. F., Rivoltinin, L., Topahan, S. L., Mlki, T., and Rosenberg, S. A. (1994) Cloning of the gene coding for a shared human melanoma antigen recogmsed by autologous T cells infiltrating into tumour. Proc. Natl. Acad. Sci. USA 91, 3515–3519.PubMedCrossRefGoogle Scholar
  8. 8.
    Mandelboim, O., Berke, G., Fridkm, M., Feldman, M., Eisenstein, M., and Elsenbach, L. (1994) CTL induction by a turnour-associated antigen octapeptlde derived from a murine lung carcinoma. Nature 369, 67–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slmgluff, C. L., Jr. (1994) Identification of a peptide recognised by five melanoma-specific human cytotoxic T cell lines. Science 264, 716–719.PubMedCrossRefGoogle Scholar
  10. 10.
    Henderson, R. A., Cox, A. L., Sakaguchi, K., Appella, E., Shabanowitz, J., Hunt, D. F., and Engelhard, V. H. (1993) Direct identification of an endogenous peptide recognised by multiple HLA-A2.1-specific cytotoxic T cells Proc. Natl. Acad Sci. USA 90, 10,275–10,279.PubMedCrossRefGoogle Scholar
  11. 11.
    Topalian, S. L., Rivoltinin, L., Mancini, M., Markus, N. R., Robbins, P. F., Kawakami, Y., and Rosenberg, S. A. (1994) Human CD4+ T cells specifically recognise a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA 91, 9461–9465.PubMedCrossRefGoogle Scholar
  12. 12.
    Stuhler, G. and Walden, P. (1993) Collaboration of helper and cytotoxm T-lymphocytes. Eur. J. Immunol. 23, 2279–2286.PubMedCrossRefGoogle Scholar
  13. 13.
    Shirai, M., Pendleton, C. D., Ahlers, J., Takeshita, T., Newman, M., and Berzofsky, J. A. (1994) Helper-cytotoxic T lymophocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. immunol. 152, 549–556.PubMedGoogle Scholar
  14. 14.
    Yanuck, M., Carbone, D. P., Pendleton, D. C., Tsukui, T., Winter, S. F., Minna, J. D., and Berzofsky, J. A. (1993) A mutant p53 tumour suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res. 53, 3257–3261.PubMedGoogle Scholar
  15. 15.
    Houbiers, J. G., Nigjman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M., and Mehef, C J. (1993) In vitro induction of human cytotoxic T lymophocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23, 2072–2077.PubMedCrossRefGoogle Scholar
  16. 16.
    Peace, D. J., Chen, W., Nelson, H., and Cheever, M. A. (1991) T cell recognition of transforming proteins encoding by mutated ras proto-oncogenes. J. Immunol. 146, 2059–2065.PubMedGoogle Scholar
  17. 17.
    Jung, S. and Schulesener, H. J. (1991) Human T lymophocytes recogmze a peptide of single point-mutated, oncogenic ras proteins. J. Exp. Med. 173, 273–276.PubMedCrossRefGoogle Scholar
  18. 18.
    Fenton, R. G., Taub, D. D., Kwak, L. W., Smith, M. R., and Longo, D. L. (1993) Cytotoxic T-cell response and zn vivo protection against tumour cells harboring activated ras protooncogenes. J. Natl. Cancer Inst. 85, 1294–1301.PubMedCrossRefGoogle Scholar
  19. 19.
    Townsend, A., Ohlen, C., Rogers, M., Edwards, J., Mukherjee, S., and Bastin, J. (1994) Source of unique tumour antigens. Nature 371, 662.PubMedCrossRefGoogle Scholar
  20. 20.
    Chattopadhyay, P., Starkey, J., Morrow, W. J. W., and Raychaudhuri, S. (1992) Murine monoclonal anti-iodiotype antibody breaks unresponsiveness and induces a specific antibody response to human melanoma associated proteoglycan antigen in cynomolgus monkeys. Proc. Natl. Acad. Sci. USA 89, 2684–2688.PubMedCrossRefGoogle Scholar
  21. 21.
    Durrant, L. G., Denton, G. W. L., Jacobs, E., Mee, M., Moss, R., Austin, E. G., Baldwin, R. W., Hardcastle, J. D., and Robins, R. A (1992) Anti-colorectal tumour cellular and humoral responses inducted by an idiotypic replica of carcmoembryomc antigen. Int. J. Cancer 50, 811–816.PubMedCrossRefGoogle Scholar
  22. 22.
    Bashford, J. L., Robins, R. A., and Price, M. R. (1993) Development of an anti-iodiotypic antibody reactive with an antibody defining the epitope RPAP in the MUC-1 epithelial mucin core. Znt. J. Cancer 54, 778–783.CrossRefGoogle Scholar
  23. 23.
    Austm, E. B., Robins, R. A., Durrant, L. G., Price, M. R., and Baldwin, R. W. (1989) Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36. Immunology 67, 525–530.Google Scholar
  24. 24.
    Durrant, L. G., Doran, M., Austin, E. B., and Robins, R. A. (1995) Induction of cellular immune responses by a murme monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int. J. Cancer. 61, 62–66.PubMedCrossRefGoogle Scholar
  25. 25.
    Austin, E. B., Robms, R. A., Baldwin, R. W., and Durrant, L. G. (1991) Induction of delayed type hypersensitity to human tumour cells with a human monoclonal anti-idiotypic antibody. J. Natl. Cancer Inst. 83, 1245–1248.PubMedCrossRefGoogle Scholar
  26. 26.
    Dun-ant, L. G., Byers, V. S., Scamon, P. J., Rodvien, R., Grant, K., Robins, R. A., Marksman, R. A., and Baldwm, R. W. (1989) Humoral nnmune responses to XMMCO-791 RTA immunotoxm in colorectal cancer paltents. Clzn. Exp. Immunol. 15, 258–264.Google Scholar
  27. 27.
    Robins, R. A., Denton, G. W. L., Hardcastle, J. D., Austm, E. B., Baldwin, R. W., and Durrant, L. G. (1991) Antitumor immune response and mterleukin 2 production inducted in colorectal cancer patients by immunization with human monoclonal anti-idiotype antibody. Cancer Res. 51, 5425–5429.PubMedGoogle Scholar
  28. 28.
    Denton, G. W. L., Durrant, L. G., Hardcastle, J. D., Austin, E. B., Sewell, H. F., and Robins, R. A. (1994) Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int. J. Cancer 57, 10–14.PubMedCrossRefGoogle Scholar
  29. 29.
    Williams, W. V., London, S. D., Werner, D. B., Wadsworth, S., Berzofsky, J. A., Robey, F., Rubin, D. H., and Greene, M. I. (1989) Immune response to a molecularly defined internal image idiotope. J, Immunol. 142, 4392–4400.Google Scholar
  30. 30.
    Chen, Z. J., Yang, H., Kageshita, R., and Ferrone, A. (1991) Human high-molecular-weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody Tk7-271. Cancer Res. 51, 4790–4797.PubMedGoogle Scholar
  31. 31.
    Pohl, C., Renner, C., Schwonzen, M., Sieber, M., Lorenz, P., Pfreundschuh, M., and Diehl, V. (1992) Anti-idiotype vaccine against Hodgkins lymphoma-induction of B-cell and T-cell immunity across species barriers agamst Cd30 antigen by murme monoclonal internal image antibodies. Int. J. Cancer 50, 958–967.PubMedCrossRefGoogle Scholar
  32. 32.
    Irvine, K. and Schlom, J. (1993) Induction of delayed type hypersensitivity responses by monoclonal antibodies to tumour-cells expressing carcmembryonic antigen and tumour associated glycoprotein-72. Cancer Immunol. Immunother. 36, 281–292.PubMedCrossRefGoogle Scholar
  33. 33.
    Saleh, M S., Stapleton, J. D., Khazaeli, M. B., and LoBuglio, A. F. (1993) Generation of a human monoclonal anti-idiotype antibody that mimics the GD2 antigen. J. Immunol. 151, 2290–2298.Google Scholar
  34. 34.
    Pride, M. W., Shi, H., Anchin, J. M., Linthicum, D. S., LoVerde, P. T., Thakur, A., and Thanavala, Y. (1992) Molecular mimicry of hepatitis B surface antigen by an anti-idiotype derived synthetic peptide. Proc. Natl. Acad. Sci. USA 89, 11,900–11,904.PubMedCrossRefGoogle Scholar
  35. 35.
    Raychaudhuri, S., Kang, C. Y., Kaveri, S. V., Kieber-Emmons, T., and Kohler, H. (1990) Tumor idiotype vaccines. VII. Analysis and correlation of structural, idiotypic, and biologic properties of protective and nonprotective Ab2. J. Immunol. 145, 760–767.PubMedGoogle Scholar
  36. 36.
    Durrant, L. G., Buckley, T. J. D., Denton, G. W. L., Hardcastle, J. D., Sewell, H. F., and Robins, R. A. (1994) Enhanced cell mediated tumour killing in patients unmunised with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res. 54, 4837–4840.PubMedGoogle Scholar
  37. 37.
    Barnd, D., Lan, M., Metzgar, R., and Firm, O. (1989) Specific MHC-unrestricted recognition of tumour associated mucins by cytotoxic T cells. Proc. Natl. Acad. Sci. USA 86, 7159–7163.PubMedCrossRefGoogle Scholar
  38. 38.
    Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadtmitriou, J., McKenzie, I. R., Bast, R. C., and Finn, O. J. (1991) Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recogmse an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51, 2908–2916.PubMedGoogle Scholar
  39. 39.
    Jerome, K. R., Domenech, N., and Finn, O. J. (1992) Tumour-associated epitopes on Epstein-Barr virus-immortalised B-cells and Burkitt’s lymphomas transfected with epithelial mucin complementary DNA. Cancer Res. 52, 5985–5990.PubMedGoogle Scholar
  40. 40.
    Jerome, K. R., Domenech, N., and Finn O. J. (1993) Tumour-specific cytatoxlc T lymphocyte clones from patients with breast and pancreatic adenocarcinoma recognise EBV-immortalised B cells transfected with polymorphic epithelial mucin cDNA. J. Immunol. 151, 1654–1662.PubMedGoogle Scholar
  41. 41.
    Bu, D., Domenech, N., Lewis, J., Taylor-Papadimitriou, J., and Finn, O. J. (1993) Recombinant vaccinia mucin vector; in vztro analysis of expression of tumour-associated epitopes for antibody and human cytotoxic T-cell recognition. J. Immunother. 14, 127–135.CrossRefGoogle Scholar
  42. 42.
    Srivastava, P. K. (1993) Peptide-binding heat-shock proteins in the endoplasmic reticulum: role in immune response to cancer and in antigen presentation. Adv. Cancer Res. 62, 153–177.PubMedCrossRefGoogle Scholar
  43. 43.
    Li, Z. and Srivastava, P. K. (1993) A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation. Behring Inst. Mitt. 35, 37–47.Google Scholar
  44. 44.
    Blachere, N. E., Udono, H., Janetzki, S., Li, Z., Heike, M., and Srivastava, P. K. (1993) Heat-shock protein vaccines against cancer. J. Immunother. 14, 352–356.CrossRefGoogle Scholar
  45. 45.
    Gruichard, G., Benkuane, N., Zeder-Lutz, G., van Regenmortel, M. H., Briand, J. P., and Muller, S. (1994) Antigenic mimicry of natural L-peptides with retroinverso peptidomimetws. Proc. Natl. Acad. Sci. USA 96, 9765–9769.CrossRefGoogle Scholar
  46. 46.
    Celis, E., Tsai, V., Crinn, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., and Serra, H. M. (1994) Induction of anti-tumour cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91, 2105–2109.PubMedCrossRefGoogle Scholar
  47. 47.
    Comy, R. M., Lobugbo, A. F., Kantor, J., Schlom, J., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. I., Abrams, S., and Curiel, D. T. (1994) Immune-response to a carcinoembryomc antigen polynucleotide vaccine. Cancer Res. 54, 1164–1168.Google Scholar
  48. 48.
    Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., and Brose, K. (1993) Vaccmation with irradiated tumour cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumour immunity. Proc. Natl. Acad Sci. USA 90, 3539–3543.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc, Totowa, NJ 1996

Authors and Affiliations

  • Lindy G. Durrant
    • 1
  • T. J. Declan Buckley
    • 1
  1. 1.Department of Clinical OncologyCity HospitalNottinghamUK

Personalised recommendations